CD33 and neoplasm: Studies using co-transduction of CARs that showed meaningful in vitro and in vivo control of AML tumor growth were developed by Atilla et al. targeting CLL-1 in combination with either CD123 or CD33 [147] and by Scherer et al. targeting CD70 with either CD123 or CLL-1 [148] (Table 3).